临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 105826-92-4

Tropisetron HCl

中文名称:盐酸托烷司琼
CAS号:105826-92-4
分子式: C17H20N2O2.HCl 分子量: 320.81
产品形式: Hydrochloride
研发状态: Unknown status
研发用途: Postoperative Cognitive Dysfunction; Postoperative Delirium
研究机构: Beijing Chao Yang Hospital
研发日期: November 1 2020
研发阶段: Phase 4
Tropisetron HCl (ICS 205-930) is a potent and selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist, used to treat nausea and vomiting following chemotherapy.

CAS: 105816-04-4

Nateglinide

中文名称:那格列奈
CAS号:105816-04-4
分子式: C19H27NO3 分子量: 317.42
产品形式: free base
研发状态: Completed
研发用途: Type 2 Diabetes Mellitus
研究机构: Ajou University School of Medicine; Korea University Guro Hospital; Hanyang University; Inha University Hospital; Kyunghee University Medical Center; Myongji Hospital; Bundang CHA Hospital; Wonju Severance Christian Hospital; Hallym University Medical Center
研发日期: April 24 2009
研发阶段: Phase 4
Nateglinide (Starlix,A-4166,SDZ DJN 608) is an insulin secretagog agent that lowers blood glucose levels by stimulating insulin secretion from the pancreas.

CAS: 1058137-23-7

Lucitanib (E3810) hydrochloride

中文名称:6-[[7-[(1-氨基环丙基)甲氧基]-6-甲氧基-4-喹啉基]氧基]-N-甲基-1-萘甲酰胺
CAS号:1058137-23-7
分子式: C26H26ClN3O4 分子量: 479.96
产品形式: Hydrochloride
研发状态: Suspended
研发用途: Advanced Solid Tumor; Gynecologic Cancer
研究机构: Clovis Oncology Inc.; Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial Groups (ENGOT)
研发日期: July 29 2019
研发阶段: Phase 1 : Phase 2
Lucitanib (E-3810, AL3810) hydrochloride is a dual inhibitor of Vascular endothelial growth factor receptor (VEGFR) and Fibroblast growth factor receptor (FGFR). Lucitanib hydrochloride (E-3810, AL3810) potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50 of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.

CAS: 1057249-41-8

SNS-314

中文名称:N-(3-氯苯基)-N'-[5-[2-(噻吩并[3,2-D]嘧啶-4-基氨基)乙基]-2-噻唑基]脲
CAS号:1057249-41-8
分子式: C18H15ClN6OS2 分子量: 430.93
产品形式: Mesylate
研发状态: Completed
研发用途: Advanced Solid Tumors
研究机构: Sunesis Pharmaceuticals
研发日期: Aug-07
研发阶段: Phase 1
SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.

CAS: 1056901-62-2

AT13148

中文名称:(+)-(S)-2-氨基-1-(4-氯苯基)-1-[4-(1H-吡唑-4-基)苯基]乙醇
CAS号:1056901-62-2
分子式: C17H16ClN3O 分子量: 313.78
产品形式: free base
研发状态: Completed
研发用途: Advanced Solid Tumours
研究机构: Cancer Research UK
研发日期: May-12
研发阶段: Phase 1
AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

CAS: 1056634-68-4

Momelotinib (CYT387)

中文名称:莫洛替尼
CAS号:1056634-68-4
分子式: C23H22N6O2 分子量: 414.46
产品形式: free base
研发状态: Completed
研发用途: Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis
研究机构: Sierra Oncology LLC - a GSK company
研发日期: Nov-10
研发阶段: Phase 2
Momelotinib (CYT387, LM-1149 , CYT11387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Momelotinib (CYT387) induces apoptosis and autophagy. Phase 3.